|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM328881716 |
| 003 |
DE-627 |
| 005 |
20250302074906.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108814
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1096.xml
|
| 035 |
|
|
|a (DE-627)NLM328881716
|
| 035 |
|
|
|a (NLM)34343708
|
| 035 |
|
|
|a (PII)S1521-6616(21)00151-0
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Dehgani-Mobaraki, Puya
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 09.09.2021
|
| 500 |
|
|
|a Date Revised 21.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Better understanding of antibody responses against SARS-CoV-2 after natural infection might provide valuable insights into the future implementation of vaccination policies. Longitudinal analysis of IgG antibody titers was carried out in 32 recovered COVID-19 patients based in the Umbria region of Italy for 14 months after Mild and Moderately-Severe infection.Two FDA-approved immunoassays against SARS-CoV-2 Nucleocapsid protein (NCP) and anti-spike-receptor binding domain (S-RBD) were used for sequential serological tests at different time points. The demographics,clinical history and symptom profile associated with the magnitude and longevity of antibody responses were also analyzed. Anti-S-RBD IgG persisted in 96.8% (31 of 32) subjects at 14 months. Patients reporting loss of smell and taste during the clinical course of the disease developed significantly higher antibody titers. Anti-NCP IgG seronegative patients(n=7) at 10 months, tested positive for anti-S-RBD IgG at 12,13 and 14 months emphasizing on a higher false-negative rate for NCP protein-based antibody assays. This study also highlights the importance of adopting specific immunoassays for routine estimation of antibody titers and the decreased rate of re-infections in recovered patients
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Observational Study
|
| 650 |
|
4 |
|a Coronavirus
|
| 650 |
|
4 |
|a Covid19
|
| 650 |
|
4 |
|a Humoral immunity
|
| 650 |
|
4 |
|a SARS-CoV-2
|
| 650 |
|
4 |
|a neutralizing antibodies
|
| 650 |
|
7 |
|a Antibodies, Viral
|2 NLM
|
| 650 |
|
7 |
|a COVID-19 Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin M
|2 NLM
|
| 700 |
1 |
|
|a Zaidi, Asiya Kamber
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yadav, Nidhi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Floridi, Alessandro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Floridi, Emanuela
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 230(2021) vom: 30. Sept., Seite 108814
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:230
|g year:2021
|g day:30
|g month:09
|g pages:108814
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108814
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 230
|j 2021
|b 30
|c 09
|h 108814
|